R W Downs1, A M Moffett, A Ghosh, D A Cox, S A Dowsett, K Harper. 1. Program for Osteoporosis and Bone Health, Division of Endocrinology and Metabolism, Virginia Commonwealth University, 1101 E Marshall Street, 7-015, P.O. Box 980111, Richmond, VA 23298-0111, USA. rdowns@mcvh-vcu.edu
Abstract
UNLABELLED: In this Phase 2 study of postmenopausal women with low bone, arzoxifene (a selective estrogen receptor modulator (SERM)) significantly reduced bone turnover marker levels and increased bone mineral density (BMD) versus placebo. Arzoxifene generally had greater effects on bone turnover and BMD than raloxifene, a SERM in current clinical use. Arzoxifene's safety profile appeared similar to raloxifene. INTRODUCTION: This 6-month, Phase 2, double-blind, placebo- and raloxifene-controlled study was designed to assess the effects of arzoxifene on bone turnover and overall safety in postmenopausal women with low bone mass. METHODS:Postmenopausal women (N = 219; mean age, 59 years) with a T-score between -1 and -2.5 were randomly assigned to daily arzoxifene 5, 10, 20, or 40 mg, raloxifene 60 mg, or placebo. All received daily calcium. RESULTS: All arzoxifene doses significantly reduced osteocalcin (primary endpoint), type 1 collagen C-telopeptide, bone specific alkaline phosphatase, and procollagen typeI amino-terminal propeptide versus placebo, and increased lumbar spine BMD. Arzoxifene generally had greater effects on bone turnover and BMD than raloxifene. Arzoxifene decreased cholesterol, low-density lipoprotein cholesterol, and fibrinogen versus placebo. Endometrial thickness change with arzoxifene was not significantly different from placebo or raloxifene; no cases of endometrial hyperplasia or adenocarcinoma were observed. Adverse event reporting with arzoxifene was similar to that with raloxifene, as were hot flush and night sweat reporting. CONCLUSIONS:Arzoxifene suppressed bone turnover and increased BMD. Within the limitations of this study, the endometrial safety profile of arzoxifene appeared similar to that of raloxifene. While no clear dose effect was evident, arzoxifene 20 and 40 mg/day appeared the optimal doses for reducing bone turnover.
RCT Entities:
UNLABELLED: In this Phase 2 study of postmenopausal women with low bone, arzoxifene (a selective estrogen receptor modulator (SERM)) significantly reduced bone turnover marker levels and increased bone mineral density (BMD) versus placebo. Arzoxifene generally had greater effects on bone turnover and BMD than raloxifene, a SERM in current clinical use. Arzoxifene's safety profile appeared similar to raloxifene. INTRODUCTION: This 6-month, Phase 2, double-blind, placebo- and raloxifene-controlled study was designed to assess the effects of arzoxifene on bone turnover and overall safety in postmenopausal women with low bone mass. METHODS: Postmenopausal women (N = 219; mean age, 59 years) with a T-score between -1 and -2.5 were randomly assigned to daily arzoxifene 5, 10, 20, or 40 mg, raloxifene 60 mg, or placebo. All received daily calcium. RESULTS: All arzoxifene doses significantly reduced osteocalcin (primary endpoint), type 1 collagen C-telopeptide, bone specific alkaline phosphatase, and procollagen type I amino-terminal propeptide versus placebo, and increased lumbar spine BMD. Arzoxifene generally had greater effects on bone turnover and BMD than raloxifene. Arzoxifene decreased cholesterol, low-density lipoprotein cholesterol, and fibrinogen versus placebo. Endometrial thickness change with arzoxifene was not significantly different from placebo or raloxifene; no cases of endometrial hyperplasia or adenocarcinoma were observed. Adverse event reporting with arzoxifene was similar to that with raloxifene, as were hot flush and night sweat reporting. CONCLUSIONS:Arzoxifene suppressed bone turnover and increased BMD. Within the limitations of this study, the endometrial safety profile of arzoxifene appeared similar to that of raloxifene. While no clear dose effect was evident, arzoxifene 20 and 40 mg/day appeared the optimal doses for reducing bone turnover.
Authors: Elizabeth Barrett-Connor; Lori Mosca; Peter Collins; Mary Jane Geiger; Deborah Grady; Marcel Kornitzer; Michelle A McNabb; Nanette K Wenger Journal: N Engl J Med Date: 2006-07-13 Impact factor: 91.245
Authors: A D Palkowitz; A L Glasebrook; K J Thrasher; K L Hauser; L L Short; D L Phillips; B S Muehl; M Sato; P K Shetler; G J Cullinan; T R Pell; H U Bryant Journal: J Med Chem Date: 1997-05-09 Impact factor: 7.446
Authors: Ethel S Siris; Steven T Harris; Richard Eastell; Jose R Zanchetta; Stefan Goemaere; Adolfo Diez-Perez; John L Stock; Jingli Song; Yongming Qu; Pandurang M Kulkarni; Suresh R Siddhanti; Mayme Wong; Steven R Cummings Journal: J Bone Miner Res Date: 2005-05-16 Impact factor: 6.741
Authors: Elizabeth Barrett-Connor; Deborah Grady; Andreas Sashegyi; Pamela W Anderson; David A Cox; Krzysztof Hoszowski; Pentti Rautaharju; Kristine D Harper Journal: JAMA Date: 2002-02-20 Impact factor: 56.272
Authors: Somnath Sarkar; Bruce H Mitlak; Mayme Wong; John L Stock; Dennis M Black; Kristine D Harper Journal: J Bone Miner Res Date: 2002-01 Impact factor: 6.741
Authors: Marc C Hochberg; Susan Greenspan; Richard D Wasnich; Paul Miller; Desmond E Thompson; Philip D Ross Journal: J Clin Endocrinol Metab Date: 2002-04 Impact factor: 5.958
Authors: B Ettinger; D M Black; B H Mitlak; R K Knickerbocker; T Nickelsen; H K Genant; C Christiansen; P D Delmas; J R Zanchetta; J Stakkestad; C C Glüer; K Krueger; F J Cohen; S Eckert; K E Ensrud; L V Avioli; P Lips; S R Cummings Journal: JAMA Date: 1999-08-18 Impact factor: 56.272